Anxiety Treatment in New Haven: Therapy, Medication, or Interventional Care? A Side-by-Side Comparison

If anxiety has begun controlling your sleep, concentration, relationships, or daily decisions, you may be wondering which treatment is right for you: therapy, medication, or something more advanced.

The answer is rarely identical for every person. Anxiety disorders involve interacting brain circuits, learned avoidance patterns, stress hormones, sleep, medical conditions, and sometimes depression, ADHD, OCD, or bipolar disorder. In simple terms, your brain’s threat-detection system may be acting like a smoke alarm that has become too sensitive. Treatment helps recalibrate that alarm, not by dismissing your fear, but by helping your nervous system respond more accurately.

At Light-tunnel Behavioral Health Services Inc. in New Haven, care is personalized around your symptoms, history, goals, treatment response, and preferences. Psychiatric care may include therapy, medication management, and interventional options when clinically appropriate. One of the psychiatric providers featured in the practice is Dr. Omolola Aragbada, PMHNP.

The short answer: there is no single “best” anxiety treatment

Therapy, medication, and interventional care are not always competing choices. Many people benefit from a stepped or combined approach.

Pathway 1: Therapy for anxiety

CBT: changing the anxiety cycle

Cognitive behavioral therapy, or CBT, helps you identify the connection between thoughts, body sensations, emotions, and behaviors. For example:

1. You notice a racing heartbeat.
2. You interpret it as danger.
3. Your fear increases.
4. You avoid the situation.
5. Avoidance briefly lowers distress but teaches the brain that the situation was unsafe.

CBT interrupts this cycle through cognitive restructuring, behavioral experiments, coping skills, and gradual exposure.

In a large randomized controlled trial involving young people with generalized anxiety disorder, separation anxiety disorder, or social anxiety disorder, CBT and sertraline were each more effective than placebo, while the combination produced the highest response rate (Walkup et al., 2008). Although results in adults and children cannot be assumed to be identical, the study illustrates why combined care may be helpful when symptoms are substantial.

Exposure and ERP

Exposure therapy gradually helps you approach feared situations instead of organizing your life around avoidance. For OCD, the specialized form is exposure and response prevention (ERP). You learn to face an anxiety trigger while reducing rituals, reassurance-seeking, or other behaviors intended to neutralize fear.

Exposure is not forced or careless. It is planned collaboratively, paced appropriately, and adjusted to your level of readiness.

ACT: making room for difficult emotions

Acceptance and commitment therapy, or ACT, focuses less on eliminating every anxious thought and more on changing your relationship with those thoughts. You practice noticing fear without automatically obeying it, then taking actions connected to your values.

Therapy may be a strong starting point when you:

• Want practical skills rather than medication alone
• Are ready to examine avoidance patterns
• Experience panic, phobias, social anxiety, or worry
• Prefer a treatment with no medication-related side effects
• Want support processing grief, trauma, relationships, or life transitions

Pathway 2: Medication management

Medication works through physiological systems involved in arousal, mood, threat processing, and emotional regulation. Think of neurotransmitters as communication signals between nerve cells. Medication does not erase your personality; it may help reduce excessive “static” so your brain can use skills more effectively.

SSRIs and SNRIs are commonly considered first-line medications for several anxiety disorders and may be particularly useful when anxiety occurs with depression. A network meta-analysis of randomized trials found that multiple first-line medications for generalized anxiety disorder were more effective than placebo, with differences in tolerability and response across medications (Slee et al., 2019).

A psychiatric evaluation may also consider:

• Buspirone: often used for generalized anxiety; its effects usually build gradually.
• Hydroxyzine: may provide short-term relief but can cause sedation and should be used carefully.
• Beta blockers: sometimes used for physical symptoms of performance anxiety, such as tremor or rapid heartbeat.
• Benzodiazepines: can provide rapid relief but require caution because of tolerance, dependence, sedation, impaired coordination, and interaction risks with alcohol or opioids.

Medication management is not simply “being given a prescription.” It involves reviewing your diagnosis, medical history, sleep, substances, current medications, side effects, and treatment goals. It may also include medication management for depression when anxiety and depression are intertwined.

Do:

• Tell your provider about all medications, supplements, alcohol, cannabis, and other substances.
• Ask how long a medication trial may take.
• Report worsening agitation, unusual mood elevation, suicidal thoughts, allergic reactions, or severe side effects.
• Take medication only as prescribed.

Avoid:

• Stopping an SSRI, SNRI, benzodiazepine, or other psychiatric medication abruptly.
• Sharing medication with another person.
• Mixing sedating medications with alcohol or opioids unless specifically directed by a clinician.
• Assuming that a medication that helped someone else is automatically right for you.

Pathway 3: Interventional care when anxiety has not responded

Interventional psychiatry may be considered when symptoms remain disabling despite adequate therapy, medication trials, or both. The key distinction is whether anxiety is the primary disorder or whether depression is driving much of the anxiety.

TMS for comorbid depression and anxiety

Transcranial magnetic stimulation, or TMS, uses magnetic pulses to influence neural circuits involved in mood regulation. For patients with treatment-resistant depression and significant anxiety symptoms, TMS may reduce both symptom clusters.

BrainsWay Deep TMS is one of the most researched Deep TMS systems. It uses an H-coil design to stimulate a broader volume of prefrontal tissue. TMS is generally delivered as an outpatient treatment while you remain awake.

Evidence for TMS as a primary treatment for generalized anxiety disorder is still developing. A randomized, double-blind, sham-controlled pilot trial found that repetitive TMS targeting the right dorsolateral prefrontal cortex could reduce generalized anxiety symptoms, but the sample was small and additional research is needed (Diefenbach et al., 2016).

For panic disorder with comorbid major depression, a randomized sham-controlled trial found greater improvement in panic symptoms with active rTMS than sham treatment, while effects on depression were less clear (Mantovani et al., 2013). This is why a careful diagnostic evaluation matters: TMS may be more appropriate when anxiety is closely connected to treatment-resistant depression than when anxiety is the only concern.

Spravato®/esketamine when depression is the driver

Spravato® is a branded form of intranasal esketamine approved for specific depressive indications, including treatment-resistant depression under regulated clinical supervision. It is not a general-purpose anxiety medication.

When severe depression is driving hopelessness, agitation, withdrawal, or anxious distress, esketamine may be discussed if you meet clinical and safety criteria. Treatment requires monitoring, and you should not drive yourself home afterward. Learn more about Spravato treatment in New Haven.

Telehealth appointment or in-person appointment?

An in-person appointment may feel more supportive if you want direct connection, a dedicated clinical environment, or help staying focused outside your home. It may also be useful when a clinician needs to observe certain physical or behavioral symptoms closely.

A telehealth appointment can reduce transportation barriers and make care easier to fit around work, school, caregiving, mobility limitations, or social anxiety. For some people, beginning from a familiar environment lowers the threshold for seeking help.

Neither format is universally superior. The best choice depends on privacy, safety, technology, clinical needs, and the type of service. Light-tunnel Behavioral Health Services Inc. offers personalized behavioral health care with both convenience and continuity in mind. You can also explore the practice’s anxiety treatment resources.

Insurance versus self-pay care

Light-tunnel Behavioral Health Services Inc. accepts a wide range of major insurance plans. Insurance may reduce out-of-pocket costs, but some services, particularly advanced treatments, may involve eligibility requirements, deductibles, or prior authorization.

Self-pay clients may benefit from:

• Transparent fees discussed before care begins
• Direct access without waiting for insurance authorization delays
• Psychiatric evaluation and diagnostic clarification
• Medication management and therapy
• TMS evaluation and treatment when appropriate
• Spravato/esketamine evaluation when clinically appropriate
• Greater flexibility when insurance limits a particular service

Self-pay does not mean skipping clinical safeguards. You still receive an individualized assessment, informed consent, safety screening, and treatment recommendations based on medical necessity. Ask the practice about current fees, superbills, reimbursement documentation, and which services may be eligible for insurance coverage.

How to choose your next step

Consider starting with:

• Therapy if avoidance, fear-based thinking, or life stressors are central.
• Medication management if symptoms are persistent, severe, or interfering with sleep and functioning.
• Combined therapy and medication if you need both symptom relief and long-term coping skills.
• TMS evaluation if treatment-resistant depression is present with significant anxiety.
• Spravato/esketamine evaluation if treatment-resistant depression is the primary clinical driver.

At Light-tunnel Behavioral Health Services Inc., Dr. Omolola Aragbada, PMHNP, and the broader care team can help you compare options rather than forcing you into a one-size-fits-all pathway.

Medical safety disclaimer and emergency resources

This article is for educational purposes only. It does not diagnose anxiety, prescribe medication, establish a provider-patient relationship, or determine whether TMS or Spravato/esketamine is appropriate for you. Treatment decisions require a complete psychiatric and medical evaluation.

If you may harm yourself or someone else, cannot remain safe, are experiencing psychosis, or have a medical emergency:

• Call or text 988 in the United States for the Suicide & Crisis Lifeline.
• Call 911 or go to the nearest emergency department for immediate danger.
• Do not wait for a routine therapy, medication, telehealth, or TMS appointment during a crisis.

References

1. Walkup, J. T., Albano, A. M., Piacentini, J., et al. (2008). Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. New England Journal of Medicine, 359(26), 2753–2766. https://doi.org/10.1056/NEJMoa0804633
2. Slee, A., Nazareth, I., Bondaronek, P., et al. (2019). Pharmacological treatments for generalized anxiety disorder: A systematic review and network meta-analysis. The Lancet, 393(10173), 768–777. https://doi.org/10.1016/S0140-6736(18)31793-8
3. Diefenbach, G. J., Bragdon, L. B., Zertuche, L., et al. (2016). Repetitive transcranial magnetic stimulation for generalized anxiety disorder: A pilot randomized, double-blind, sham-controlled trial. British Journal of Psychiatry, 209(3), 222–228. https://doi.org/10.1192/bjp.bp.115.168203
4. Mantovani, A., Aly, M., Dagan, Y., et al. (2013). Randomized sham-controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for panic disorder with comorbid major depression. Journal of Affective Disorders, 144(1–2), 153–159. https://doi.org/10.1016/j.jad.2012.05.038
5. Garakani, A., Murrough, J. W., Freire, R. C., et al. (2020). Pharmacotherapy of anxiety disorders: Current and emerging treatment options. Frontiers in Psychiatry, 11, 595584. https://doi.org/10.3389/fpsyt.2020.595584
6. Rodrigues, P. A., Zaninotto, A. L., Neville, I. S., et al. (2019). Transcranial magnetic stimulation for the treatment of anxiety disorder. Neuropsychiatric Disease and Treatment, 15, 2743–2761. https://doi.org/10.2147/NDT.S201407

Next in the Series

Breaking the Loop: How OCD Therapy and TMS Can Help You Regain Control